Cephalon Adds Warning On Life-Threatening Skin Reaction To Provigil
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA requests updated labeling recommending the wakefulness drug be discontinued if a rash or hypersensitivity reaction occurs.
You may also be interested in...
FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash
Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.
Nuvigil May Be Further Delayed As FDA Reviews Side Effect Profile
Cephalon plans to submit information to FDA within “the next few weeks.”
Merck & Co. Remains 'Very Confident' In TIGIT
Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.